Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
ORMP's Cash to Debt is ranked higher than
91% of the 1233 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ORMP: No Debt )
ORMP' s 10-Year Cash to Debt Range
Min: 6.98   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ORMP's Interest Coverage is ranked lower than
140% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ORMP: No Debt )
ORMP' s 10-Year Interest Coverage Range
Min: 128.16   Max: 9999.99
Current: No Debt

128.16
9999.99
F-Score: 1
Z-Score: 42.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -34.93
ORMP's ROE (%) is ranked higher than
72% of the 1124 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ORMP: -34.93 )
ORMP' s 10-Year ROE (%) Range
Min: -8090   Max: -54.79
Current: -34.93

-8090
-54.79
ROA (%) -33.63
ORMP's ROA (%) is ranked higher than
70% of the 1231 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. ORMP: -33.63 )
ORMP' s 10-Year ROA (%) Range
Min: -468.93   Max: -52.25
Current: -33.63

-468.93
-52.25
ROC (Joel Greenblatt) (%) -53690.91
ORMP's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 1204 Companies
in the Global Biotechnology industry.

( Industry Median: -480.34 vs. ORMP: -53690.91 )
ORMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -313200   Max: 242.89
Current: -53690.91

-313200
242.89
EBITDA Growth (%) 7.20
ORMP's EBITDA Growth (%) is ranked higher than
77% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. ORMP: 7.20 )
ORMP' s 10-Year EBITDA Growth (%) Range
Min: -10.8   Max: 57
Current: 7.2

-10.8
57
EPS Growth (%) 2.80
ORMP's EPS Growth (%) is ranked higher than
80% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ORMP: 2.80 )
ORMP' s 10-Year EPS Growth (%) Range
Min: -24.7   Max: 183
Current: 2.8

-24.7
183
» ORMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ORMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.20
ORMP's P/B is ranked higher than
83% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 5.68 vs. ORMP: 3.20 )
ORMP' s 10-Year P/B Range
Min: 0   Max: 28.2
Current: 3.2

0
28.2
EV-to-EBIT -7.29
ORMP's EV-to-EBIT is ranked higher than
83% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ORMP: -7.29 )
ORMP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -7.29

Current Ratio 22.38
ORMP's Current Ratio is ranked higher than
98% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. ORMP: 22.38 )
ORMP' s 10-Year Current Ratio Range
Min: 0.02   Max: 22.38
Current: 22.38

0.02
22.38
Quick Ratio 22.38
ORMP's Quick Ratio is ranked higher than
98% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. ORMP: 22.38 )
ORMP' s 10-Year Quick Ratio Range
Min: 0.02   Max: 22.38
Current: 22.38

0.02
22.38

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.27
ORMP's Price/Net Cash is ranked higher than
91% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 105.66 vs. ORMP: 3.27 )
ORMP' s 10-Year Price/Net Cash Range
Min: 4.97   Max: 39
Current: 3.27

4.97
39
Price/Net Current Asset Value 3.23
ORMP's Price/Net Current Asset Value is ranked higher than
90% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 37.29 vs. ORMP: 3.23 )
ORMP' s 10-Year Price/Net Current Asset Value Range
Min: 4.9   Max: 37.71
Current: 3.23

4.9
37.71
Price/Tangible Book 3.20
ORMP's Price/Tangible Book is ranked higher than
88% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. ORMP: 3.20 )
ORMP' s 10-Year Price/Tangible Book Range
Min: 4.85   Max: 35.2
Current: 3.2

4.85
35.2
Earnings Yield (Greenblatt) -13.70
ORMP's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ORMP: -13.70 )
ORMP' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.8   Max: 9.3
Current: -13.7

-12.8
9.3
Forward Rate of Return (Yacktman) 14.42
ORMP's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -6.43 vs. ORMP: 14.42 )
ORMP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: 14.42

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:OJU1.Germany
Oramed Pharmaceuticals Inc. was incorporated on April 12, 2002, under the laws of the State of Nevada. It is a pharmaceutical Company engaged in the research and development of innovative pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, rectal application of insulin, use of oral ingestible capsules or tablets for delivery other polypeptides and use of rectal application for delivery of other polypeptides. The Company is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD0801) currently in Phase 2 clinical trials. The Company plans to continue to conduct clinical trials to show the effectiveness of its technology. It filed two additional provisional patents for a suppository application to its technology portfolio. The first patent focuses on a rectal application for insulin. The second patent focuses on the usage of this rectal application to other polypeptides that at present are only available in injection. On September 16, 2008 it announced the launch of pre-clinical trials of ORMD 0901, a GLP1-analog. The Company has agreements with Vetgenerics Research G. Ziv Ltd., a clinical research organization, to conduct a toxicology trial on its oral insulin capsules. It is subject to Federal and state laws, regulations, and recommendations relating to safe working conditions, laboratory practices, the experimental use of animals, and the purchase, storage, movement, import, export, use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with research are applicable to its activities.
» More Articles for NAS:ORMP

Headlines

Articles On GuruFocus.com
Coverage Initiation Report Focuses on Oramed Pharmaceuticals Nov 11 2014 

More From Other Websites
Nasdaq stocks posting largest percentage increases Nov 19 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report Nov 14 2014
Coverage Initiation Report Focuses on Oramed Pharmaceuticals Nov 11 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Nov 04 2014
ORAMED Pharmaceuticals Clinical Data Call scheduled for 10:00 am ET today Nov 03 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 03 2014
Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes Oct 31 2014
Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes Oct 31 2014
Oramed to Present at the FireRock Annual Micro-Cap Conference Oct 24 2014
Oramed to Present at the FireRock Annual Micro-Cap Conference Oct 24 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Other Events Oct 23 2014
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in... Oct 22 2014
Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in... Oct 22 2014
Oramed to Present at Family Office & Wealth Management Conference Sep 15 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 08 2014
Oramed to Present at Upcoming Conferences Sep 03 2014
Oramed Granted Patent in Spain for Oral Administration of Insulin Aug 19 2014
Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes Aug 07 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders,... Jul 28 2014
ORAMED PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK